VIVO Stock - Meridian Bioscience, Inc.
Unlock GoAI Insights for VIVO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $333.02M | $317.90M | $253.67M | $201.01M | $213.57M |
| Gross Profit | $188.36M | $201.15M | $156.25M | $118.33M | $130.46M |
| Gross Margin | 56.6% | 63.3% | 61.6% | 58.9% | 61.1% |
| Operating Income | $55.51M | $93.03M | $61.32M | $32.70M | $31.58M |
| Net Income | $42.46M | $71.41M | $46.19M | $24.38M | $23.85M |
| Net Margin | 12.7% | 22.5% | 18.2% | 12.1% | 11.2% |
| EPS | $0.96 | $1.62 | $1.07 | $0.57 | $0.56 |
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H. pylori under the BreathID and BreathTek brand. This segment also offers respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry products for LeadCare test kits for the detection of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.
Visit WebsiteEarnings History & Surprises
VIVOEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2023 | May 4, 2023 | $0.15 | — | — | — |
Q1 2023 | Feb 2, 2023 | $0.15 | $-0.68 | -552.9% | ✗ MISS |
Q4 2022 | Nov 22, 2022 | $0.15 | $0.21 | +40.0% | ✓ BEAT |
Q3 2022 | Aug 5, 2022 | $0.16 | $0.16 | 0.0% | = MET |
Q2 2022 | May 6, 2022 | $0.48 | $0.66 | +37.5% | ✓ BEAT |
Q1 2022 | Feb 4, 2022 | $0.25 | $0.35 | +40.0% | ✓ BEAT |
Q4 2021 | Nov 12, 2021 | $0.21 | $0.24 | +14.3% | ✓ BEAT |
Q3 2021 | Aug 6, 2021 | $0.31 | $0.22 | -29.0% | ✗ MISS |
Q2 2021 | May 7, 2021 | $0.48 | $0.57 | +18.7% | ✓ BEAT |
Q1 2021 | Feb 5, 2021 | $0.42 | $0.65 | +54.8% | ✓ BEAT |
Q4 2020 | Nov 13, 2020 | $0.14 | $0.10 | -28.6% | ✗ MISS |
Q3 2020 | Aug 7, 2020 | $0.23 | $0.55 | +139.1% | ✓ BEAT |
Q2 2020 | May 8, 2020 | $0.08 | $0.23 | +187.5% | ✓ BEAT |
Q1 2020 | Feb 7, 2020 | $0.07 | $0.10 | +42.9% | ✓ BEAT |
Q4 2019 | Nov 7, 2019 | $0.09 | $0.13 | +44.4% | ✓ BEAT |
Q3 2019 | Jul 30, 2019 | $0.09 | $0.16 | +77.8% | ✓ BEAT |
Q2 2019 | Apr 30, 2019 | $0.16 | $0.19 | +18.8% | ✓ BEAT |
Q1 2019 | Jan 24, 2019 | $0.17 | $0.20 | +17.6% | ✓ BEAT |
Q4 2018 | Nov 8, 2018 | $0.16 | $0.20 | +25.0% | ✓ BEAT |
Q3 2018 | Jul 31, 2018 | $0.18 | $0.18 | 0.0% | = MET |
Latest News
Frequently Asked Questions about VIVO
What is VIVO's current stock price?
What is the analyst price target for VIVO?
What sector is Meridian Bioscience, Inc. in?
What is VIVO's market cap?
Does VIVO pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to VIVO for comparison